Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases - Wikidata - awgldk - TriplyDB

Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases

Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases

http://www.wikidata.org/entity/Q28182631

about

Aspirin Resistance in Patients with Stable Coronary Artery Disease with and without a History of Myocardial Infarction Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications [National disease management guidelines (NVL) for chronic CAD : What is new, what is particularly important?].Thrombosis and antithrombotic therapy in women Influence of sex hormones and phytoestrogens on heart disease in men and women Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort.Bleeding and first-year mortality following hip fracture surgery and preoperative use of low-dose acetylsalicylic acid: an observational cohort study.Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine.Male mice have increased thrombotic potential: sex differences in a mouse model of venous thrombosis Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia.Effect of gender difference on platelet reactivity.Assessment of Sex Differences for Treatment, Procedures, Complications, and Associated Conditions Among Adolescents Hospitalized with Crohn's Disease.Therapeutic implications of the gender-specific aspects of cardiovascular disease.Sex differences in cardiovascular drug-induced adverse reactions causing hospital admissions.Should women receive left ventricular assist device support?: findings from INTERMACS.Predictors of excess mortality after myocardial infarction in women Strategies for improving cardiovascular health in women with diabetes mellitus: a review of the evidence.Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.Does i-T744C P2Y12 Polymorphism Modulate Clopidogrel Response among Moroccan Acute Coronary Syndromes Patients?Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women.Women and the management of acute coronary syndrome.Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: a focus on the cardiomyocyte.Gender differences in cardiovascular therapy: focus on antithrombotic therapy and percutaneous coronary intervention.Gender and anti-thrombotic therapy: from biology to clinical implications.Effects of hormones on platelet aggregation.Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC.Primary and secondary prevention of ischemic heart disease in women.Factors affecting the anthelmintic efficacy of papaya latex in vivo: host sex and intensity of infection.Gender differences in the effects of cardiovascular drugs.Effects of Triflusal and Clopidogrel on the Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping Antihypertensive treatment and control in a large primary care population of 21 167 patients.Sex differences in cardiovascular function.Gender differences in long-term outcome after primary percutaneous intervention for ST-segment elevation myocardial infarction.Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy.Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment.[Sex and gender differences in pharmacotherapy].A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics

P2860

Q22306115-6600A52E-C410-4606-9CBC-AAB10B0A6670 Q26996309-27502B8B-3F7E-403E-8837-4B4CD71E48DB Q30313892-D4FF1736-1514-42C8-A16E-47A2AB54C4C5 Q33569283-657E0D6C-19EE-4F9C-9C27-87E16871BAB5 Q33721061-2976E1C5-7D18-49F9-BC66-C39B23B268F5 Q34020658-69E5B325-E388-4DB3-9B5E-ADD3EA7DD568 Q34068661-9071EE7C-16FF-41AF-A4B9-E3BA0DC8AFE0 Q34485100-42D4E3DD-6BCE-4F64-8BAF-435A293ADCE5 Q34851729-64A2EED3-3F12-4C8E-9E21-A359BB319C84 Q35156722-ACCA6571-BB33-47B6-A08C-5250EC1072D6 Q35473568-609A267F-2C60-45C2-B0D4-8CEAFBD18043 Q36219178-1483C29B-63AB-4CD5-8CF8-9F7C152B1563 Q36467824-1DD83730-7FE6-4241-8818-ECB3B33CC632 Q36468159-A8E7170F-F6FB-4894-9432-2971465E495F Q36793794-E9CCF9D4-DB4D-4D4A-9A61-1CEBD2CC44E4 Q36837908-A2AFB927-FDFA-4A05-8209-220658E4E3D1 Q36950782-84C4B0F0-998B-4DA0-A73D-662BFA17259A Q36973414-2B06DA6E-D223-4B08-ABD9-CBD6134BCC56 Q37651530-E9108A97-1101-4337-BEF9-4A0C9B91A0E8 Q37671280-220926A1-D6D6-460A-97FD-B63528B375AC Q38034238-9FEB2D36-84E4-4AAB-8F43-F55658CC714D Q38119546-6798D878-AB80-4455-94D4-18E2D7D606C3 Q38155124-35479476-7F06-4BA1-A8D8-107E98F2B4AF Q38182428-C94DA419-A353-4976-8F63-9E4B248D3AB2 Q38267476-C2DA5FF9-4F06-4EFA-A1A6-778D18AED45B Q38463317-5D4A1F23-C688-484D-B2B1-1ED517EF39B3 Q38500893-5B398F9C-6193-4A50-831D-8972A9F817A2 Q39020159-3B1A8D91-142F-4DCE-8FF3-EC73A91BEA66 Q39193538-B8A4B21D-D27C-4EF2-A1D2-D0FB2D9D5D32 Q42380287-F1428B2A-44BB-411C-B095-BE7DDF279239 Q43644632-56A8896C-254C-4B7B-B477-8B429D2A7529 Q43841771-36A2620F-3468-4206-BF47-4AE06B0324AC Q44644813-CA14587F-AD5F-4FF6-81BF-50EEEBC3BC44 Q48689443-159AFE59-0AFC-4129-BF3A-1B7F25B7A08D Q51505075-206B0BC4-9A71-4B42-BE4A-BACF43D91F89 Q52875377-C7DA93FF-EFD7-4C24-9499-E5B33B36F83D Q58294605-5C9C375B-CB59-459A-B092-D9B9489C5A17

P2860

Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases

http://www.wikidata.org/entity/Q28182631

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases

@ast

Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases

@en

Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases

@nl

type

label

Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases

@ast

Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases

@en

Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases

@nl

prefLabel

Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases

@ast

Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases

@en

Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases

@nl

P1433

Q28182631-0B6F3BD9-AEE6-408A-A342-300F28208B5E

P1476

Q28182631-00C2E953-F288-4D75-84A0-86EA25E5368B

P2093

Q28182631-28D079CD-2A15-4BA4-BE7A-AD4726E42D79

Q28182631-5FABA42C-D8BB-4C36-9EBD-695EDE321377

Q28182631-748B3CE4-A464-4D22-8945-79487A6B3A46

Q28182631-9E47352D-68A4-4F0D-A728-B79128412D2D

Q28182631-DA8D32FC-C375-4C41-9328-05CBCECE483C

P2860

Q28182631-00518E93-B458-4820-9C7F-E864570403EE

Q28182631-037122BE-3F94-4430-A171-77AE78EA961B

Q28182631-03EAD7B6-896A-4B66-BA32-454D0348984D

Q28182631-083AA8B7-6265-4106-A95B-F411074D02B1

Q28182631-08EB8331-D91F-4372-886A-1FC1BD68E68E

Q28182631-10954A78-FAFD-4602-B94C-7BC7F5094684

Q28182631-13DAC9BE-0806-4ABE-B119-0D045F528551

Q28182631-1A5CDA62-E366-4D09-A307-7684A75F399E

Q28182631-1D4F062E-7E56-461E-BF5B-AF3203393570

Q28182631-1E8AD172-4A63-4009-AD59-BB851AFAA270

P304

Q28182631-B54EE9BF-E84A-47AB-9138-871E73F1F327

P31

Q28182631-D8B722EB-E765-4AA6-9BEB-006641FC24C1

P356

Q28182631-1B67FA27-1437-4ABA-8033-979D9214EAFE

P407

Q28182631-EDF335BC-0888-4CAF-B37F-8F067036F795

P433

Q28182631-3AC771A0-F16A-4CF3-9A13-061650F421A6

P478

Q28182631-4279BEA3-860A-4FA3-BD97-7BF35CC0A761

P577

Q28182631-910BD4C7-F2C3-4A2E-B149-2699847B942F

P5875

Q28182631-4B143DE1-901F-412F-974E-EC55D8F80B70

P698

Q28182631-AF5D2D19-9F8B-44FB-AED2-9930A4DF5841

P921

Q28182631-6F934B86-81FF-45CB-B00D-024EF29C81A2

Q28182631-B6BC8537-4D96-46BD-87ED-0A2A7208E09E

P356

P1433

European Heart Journal

P1476

Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases

@en

P2093

Edeltraut Garbe

http://www.w3.org/2001/XMLSchema#string

Gert Baumann

http://www.w3.org/2001/XMLSchema#string

Karl Stangl

http://www.w3.org/2001/XMLSchema#string

Nicoline Jochmann

http://www.w3.org/2001/XMLSchema#string

Verena Stangl

http://www.w3.org/2001/XMLSchema#string

P2860

Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project

Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial)

Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke

Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study)

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

P304

1585-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHI397

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7747297

http://www.w3.org/2001/XMLSchema#string

P698

15996977

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

pharmacotherapy